ATE294875T1 - Kationische polyacrylate und poly(alkyl)acrylate oder die entsprechende acrylamide zur verwendung in synthetischen transfektions-systemen - Google Patents

Kationische polyacrylate und poly(alkyl)acrylate oder die entsprechende acrylamide zur verwendung in synthetischen transfektions-systemen

Info

Publication number
ATE294875T1
ATE294875T1 AT96935575T AT96935575T ATE294875T1 AT E294875 T1 ATE294875 T1 AT E294875T1 AT 96935575 T AT96935575 T AT 96935575T AT 96935575 T AT96935575 T AT 96935575T AT E294875 T1 ATE294875 T1 AT E294875T1
Authority
AT
Austria
Prior art keywords
poly
alkyl
acrylates
cationic
polyacrylate
Prior art date
Application number
AT96935575T
Other languages
English (en)
Inventor
Wilhelmus Everhardus Hennink
De Wetering Petra Van
Original Assignee
Octoplus B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octoplus B V filed Critical Octoplus B V
Application granted granted Critical
Publication of ATE294875T1 publication Critical patent/ATE294875T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT96935575T 1995-10-25 1996-10-25 Kationische polyacrylate und poly(alkyl)acrylate oder die entsprechende acrylamide zur verwendung in synthetischen transfektions-systemen ATE294875T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95202891 1995-10-25
US592395P 1995-10-27 1995-10-27
PCT/NL1996/000416 WO1997015680A1 (en) 1995-10-25 1996-10-25 Cationic polyacrylates and poly(alkyl) acrylates or the corresponding acrylamides for use in synthetic transfection or blocking systems

Publications (1)

Publication Number Publication Date
ATE294875T1 true ATE294875T1 (de) 2005-05-15

Family

ID=26139739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96935575T ATE294875T1 (de) 1995-10-25 1996-10-25 Kationische polyacrylate und poly(alkyl)acrylate oder die entsprechende acrylamide zur verwendung in synthetischen transfektions-systemen

Country Status (8)

Country Link
US (1) US5985573A (de)
EP (1) EP0859857B1 (de)
JP (1) JP3957084B2 (de)
AT (1) ATE294875T1 (de)
AU (1) AU7342296A (de)
DE (1) DE69634697T2 (de)
ES (1) ES2242198T3 (de)
WO (1) WO1997015680A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0965584A3 (de) * 1998-06-15 2003-12-17 Transgene S.A. Zum Einschleusen von Wirkstoffen in Zellen geeignete Polyamin-Verbindungen und diese enthaltende Zusammensetzungen
EP0965583A1 (de) * 1998-06-15 1999-12-22 Transgene S.A. Zum Einschleusen von Wirkstoffen in Zellen geeignete Polyamin-Verbindungen und diese enthaltende Zusammensetzungen
US20050153926A1 (en) * 1998-12-04 2005-07-14 Adams Christopher P. Method for the immobilization of oligonucleotides
EP1022340A1 (de) * 1999-01-21 2000-07-26 OctoPlus B.V. Stabilisierung von Zusammensetzungen die nicht-virale nukeinsäure-Transfer-Zusammensetzungen enthalten
JP2006501824A (ja) * 2002-10-03 2006-01-19 アグロシールド リミテッド ライアビリティー カンパニー 材料を損傷から保護するためのポリマー類
WO2004087228A1 (ja) * 2003-03-28 2004-10-14 Japan Science And Technology Agency 生体適合性と温度応答性を併せ持つ高分子
JP5153072B2 (ja) * 2003-04-18 2013-02-27 独立行政法人国立循環器病研究センター ベクター
JP4718766B2 (ja) * 2003-06-03 2011-07-06 テルモ株式会社 血液フィルター
ES2255659T3 (es) * 2003-08-07 2006-07-01 Octoplus Technologies B.V. Derivado cationico de (alquil) acrilamida, polimero basdo en estos derivados, y sistema de transfeccion que comprende dicho polimero.
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
EP2418281B1 (de) 2003-10-24 2016-06-01 Gencia Corporation Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
CA2561419C (en) * 2004-04-02 2013-03-19 Agroshield, Llc Compositions and methods for protecting materials from damage
WO2005097197A1 (de) * 2004-04-05 2005-10-20 Basf Aktiengesellschaft Wirkstoffhaltige polymerteilchen
EP1595534A1 (de) * 2004-05-13 2005-11-16 Universiteit Utrecht Holding B.V. Gelzusammensetzung enthaltend geladenepolymere
DE102004059792A1 (de) * 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
DE102008016275A1 (de) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102007056488A1 (de) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102008023913A1 (de) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
EP2363494A1 (de) 2007-11-22 2011-09-07 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
WO2010150089A1 (en) * 2009-06-26 2010-12-29 Cedars-Sinai Medical Center Highly efficient systems for delivery of nucleic acids
US8678201B2 (en) * 2010-06-04 2014-03-25 Goodrich Corporation Aircraft potable water system
EP2522689A1 (de) 2011-05-13 2012-11-14 Universität Bayreuth Nicht virale Transfektionssysteme
US9283072B2 (en) 2012-07-25 2016-03-15 W. L. Gore & Associates, Inc. Everting transcatheter valve and methods
US10376360B2 (en) 2012-07-27 2019-08-13 W. L. Gore & Associates, Inc. Multi-frame prosthetic valve apparatus and methods
US9144492B2 (en) 2012-12-19 2015-09-29 W. L. Gore & Associates, Inc. Truncated leaflet for prosthetic heart valves, preformed valve
US9101469B2 (en) 2012-12-19 2015-08-11 W. L. Gore & Associates, Inc. Prosthetic heart valve with leaflet shelving
US9968443B2 (en) 2012-12-19 2018-05-15 W. L. Gore & Associates, Inc. Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet
US9737398B2 (en) 2012-12-19 2017-08-22 W. L. Gore & Associates, Inc. Prosthetic valves, frames and leaflets and methods thereof
US10321986B2 (en) 2012-12-19 2019-06-18 W. L. Gore & Associates, Inc. Multi-frame prosthetic heart valve
US10966820B2 (en) 2012-12-19 2021-04-06 W. L. Gore & Associates, Inc. Geometric control of bending character in prosthetic heart valve leaflets
US9827094B2 (en) 2014-09-15 2017-11-28 W. L. Gore & Associates, Inc. Prosthetic heart valve with retention elements
CN115024861B (zh) 2017-09-27 2025-08-19 爱德华兹生命科学公司 具有机械联接的瓣叶的假体瓣膜
JP7068444B2 (ja) 2017-09-27 2022-05-16 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド 拡張可能なフレームを備えた人工弁、並びに関連するシステム及び方法
EP4470505A3 (de) 2017-10-13 2025-03-05 Edwards Lifesciences Corporation Teleskopische klappenprothese und freisetzungssystem
US11154397B2 (en) 2017-10-31 2021-10-26 W. L. Gore & Associates, Inc. Jacket for surgical heart valve
WO2019089135A1 (en) 2017-10-31 2019-05-09 W. L. Gore & Associates, Inc. Transcatheter deployment systems and associated methods
AU2018362081B2 (en) 2017-10-31 2021-05-06 Edwards Lifesciences Corporation Prosthetic heart valve
CA3078606C (en) 2017-10-31 2023-09-05 W.L. Gore & Associates, Inc. Medical valve and leaflet promoting tissue ingrowth
US11497601B2 (en) 2019-03-01 2022-11-15 W. L. Gore & Associates, Inc. Telescoping prosthetic valve with retention element
EP3952790A1 (de) 2019-04-12 2022-02-16 W.L. Gore & Associates, Inc. Ventil mit mehrteiligem rahmen und zugehörigen elastischen überbrückungsmerkmalen
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
IL307454A (en) 2021-04-07 2023-12-01 Battelle Memorial Institute Technologies for rapid design, construction, testing, learning to identify and use non-viral vectors
WO2024233936A1 (en) * 2023-05-11 2024-11-14 North Carolina State University Thrombin sensitive platelet like particles
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
JPH0463597A (ja) * 1990-06-29 1992-02-28 W R Grace & Co 細胞への遺伝子導入法およびそれに用いる細胞固定板
DE4139001A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur einschleusung von nukleinsaeuren in zellen

Also Published As

Publication number Publication date
AU7342296A (en) 1997-05-15
DE69634697D1 (de) 2005-06-09
ES2242198T3 (es) 2005-11-01
JP3957084B2 (ja) 2007-08-08
US5985573A (en) 1999-11-16
EP0859857B1 (de) 2005-05-04
WO1997015680A1 (en) 1997-05-01
DE69634697T2 (de) 2006-05-04
JP2001508641A (ja) 2001-07-03
EP0859857A1 (de) 1998-08-26

Similar Documents

Publication Publication Date Title
ATE294875T1 (de) Kationische polyacrylate und poly(alkyl)acrylate oder die entsprechende acrylamide zur verwendung in synthetischen transfektions-systemen
EP0986382A4 (de) Raf kinase hemmer
ATE247454T1 (de) Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut
UA10911C2 (uk) Біосумісhий гідрогель
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
DE59907587D1 (de) Verfahren zur Regelung des Gierverhaltens von Fahrzeugen
DE69809263D1 (de) Methoden ud system zur wahl von datensets
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
UA85036C2 (ru) Ингибитор и стимулятор пролиферации стволовых клеток и их использование
DE69425904D1 (de) Hautbräunungsmittel
CA2211868A1 (en) Methods of inhibiting corrosion using n-halo-azoles
DE69737397D1 (de) Verwendung von mif-antagonisten zur krebstherapie
ATE389023T1 (de) Kontrolle der schotendehiszenz
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE69920205D1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DE3266165D1 (en) Stable water-in-oil dispersions of water soluble cationic polymers based on dimethylaminoethyl acrylate salted or quaternary, process for their production and their use as flocculants
IT1146912B (it) Procedimento per la produzione continua di acrilammide o metacrilammide tramite microrganismi
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE338031T1 (de) Verfahren zur hemmung von korrosion unter verwendung von isomeren des chlormethylbenzotriazols
DE60036551D1 (de) VERWENDUNG VON BAKTERIELLEN ParD kis/ParD kid TOXIN-ANTITOXIN SYSTEM ZUR TÖTUNG VON EUKARYOTISCHEN ZELLEN
WO1998057990A3 (en) Methods and compositions for treating abnormal cell growth related to unwanted guanine nucleotide exchange factor activity
ATE237630T1 (de) Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
DE69713487D1 (de) Vorrichtung zur direktherstellung von eisen oder stahl unter verwendung von selbstreduzierenden eisenoxidpellets
ATE222135T1 (de) Verfarhen zur unterkühlung
BR8701331A (pt) Composicao para inibir corrosao em aguas de resfriamento industriais e processo para melhorar o desempenho de inibidores de corrosao de fosofonato em sistemas aquosos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties